The Meningitis Vaccine Project - contributing partners
Pharmaceutical work and vaccine manufacturing
Serum Institute of India Ltd
Established in 1967, the Serum Institute of India Limited (SIIL) has emerged as a major supplier of quality vaccines and the world’s largest manufacturer of measles vaccine and diphtheria-tetanus-pertussis (DTP) vaccines. It is estimated that two out of every three children immunized in the world is vaccinated by a vaccine manufactured by SIIL.
SIIL was chosen as the manufacturer of the meningococcal A conjugate vaccine following approaches to a number of other major vaccine manufacturers. The agreement of SIIL to accept technology transfer and the company's willingness to sell the vaccine for less than US$ 0.50 per dose were determining factors.
A French company based in Strasbourg, Aérial–Technology Resource Center provided expertise in the formulation and lyophilization of the meningococcal A conjugate vaccine.
Synco Bio Partners B.V
Based in the Netherlands, Synco Bio Partners B.V manufactures biopharmaceutical products, with the objective of bridging the gap between research and results. The company was the original supplier of meningococcal group A polysaccharide (MenA PS), one of the two main components of MenAfriVac.
Center for Biologics Evaluation and Research
A center of the United States Food and Drug Administration, the Center for Biologics Evaluation and Research developed the MenA PS-TT conjugation technology before its transfer to SIIL.
National Institute of Biological Standards and Control
Based in the United Kingdom of Great Britain and Northern Ireland, the National Institute of Biological Standards and Control (NIBSC) has been responsible for the independent analytical testing of intermediate and final products produced by SIIL to ensure that product specifications are met.
National Institutes of Health
Based in Bethesda, Maryland, the United States National Institutes of Health licensed the conjugation technology to SIIL.